879403-42-6

Basic information

• Product Name: (S)-N-Boc-2-aminomethylmorpholine
• Synonyms: (S)-N-Boc-2-aminomethylmorpholine;(S)-4-N-Boc-2-aminomethylmorpholine;(S)-4-Boc-2-aminomethylmorpholine;(S)-2-AMinoMethyl-4-Boc-Morpholine;(S)-2-(Aminomethyl)morpholine-4-carboxylic acid tert-butyl ester;4-Morpholinecarboxylic acid, 2-(aMinoMethyl)-, 1,1-diMethylethyl ester, (2S)-;(S)-tert-Butyl 2-(aMinoMethyl)Morpholine-4-carboxylate;tert-butyl (2S)-2-(aminomethyl)morpholine-4-carboxylate
• CAS NO: 879403-42-6
• Molecular Formula: C₁₀H₂₀N₂O₃
• Molecular Weight: 216.279
• Mol File: 879403-42-6.mol

Chemical Properties

• Boiling Point: 311℃
• Flash Point: 141℃
• Appearance: /
• Density: 1.078
• Vapor Pressure: 0.000589mmHg at 25°C
• Refractive Index: 1.477
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.37±0.29(Predicted)
• CAS DataBase Reference: (S)-N-Boc-2-aminomethylmorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-Boc-2-aminomethylmorpholine(879403-42-6)
• EPA Substance Registry System: (S)-N-Boc-2-aminomethylmorpholine(879403-42-6)

Safety Data

• Hazardous Substances Data: 879403-42-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-N-Boc-2-Aminomethylmorpholine is used as a building block for the synthesis of various biologically active molecules. Its ability to introduce the morpholine ring into complex chemical structures makes it a valuable component in the development of new drugs and pharmaceuticals.
Used in Asymmetric Synthesis:
(S)-N-Boc-2-Aminomethylmorpholine is used as a ligand in asymmetric synthesis, a technique that allows for the selective formation of one enantiomer of a chiral compound over another. This selective synthesis is crucial in the production of enantiomerically pure compounds, which often exhibit different biological activities and are essential in the pharmaceutical industry.
Used in Catalysis:
(S)-N-Boc-2-Aminomethylmorpholine also finds application as a ligand in catalysis, where it can enhance the efficiency and selectivity of various chemical reactions. Its use in catalysis contributes to the development of more sustainable and efficient synthetic routes for the production of pharmaceuticals and other chemical products.

InChI:InChI=1/C10H20N2O3/c1-10(2,3)15-9(13)12-4-5-14-8(6-11)7-12/h8H,4-7,11H2,1-3H3/t8-/m0/s1

Upstream product

• 135065-64-4 tert-butyl (2R)-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)morpholine-4-carboxylate 
• 919286-58-1 tert-butyl (2R)-2-(bromomethyl)morpholine-4-carboxylate 
• 1308849-91-3 (S)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate 
• 503455-76-3 (R)-tert-butyl 2-(((methylsulfonyl)oxy)methyl)morpholine-4-carboxylate 
• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 
• 921211-91-8 tert-butyl (2R)-2-(azidomethyl)morpholine-4-carboxylate 

Downstream Products

• 1308849-92-4 (S)-tert-butyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1308849-86-6 (S)-methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 

Relevant articles and documents

BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

The present disclosure relates to benzimidazole derivatives, a preparation method therefor and a medical use thereof. Specifically, the present disclosure relates to a benzimidazole derivative represented by the general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and its use as a therapeutic agent, in particular its use for the treatment of diseases related to P2X3 activity.

HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound hasa high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS

The present invention covers substituted Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.

BENZOIMIDAZOLE COMPOUNDS AND USES THEREOF

This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H- benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates

Identification of inhibitors of checkpoint kinase 1 through template screening

Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies. Using template screening, a fragment